Deferiprone

CAS 30652-11-0 7 current records 1 historicalSmall Molecule

Who holds supplier records for Deferiprone? 7 organisations hold a current record for Deferiprone: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (3), Canada (1), Italy (1), Israel (1) and 1 other country (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Deferiprone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/deferiprone

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 4 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Deferiprone expires 25 Oct 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Deferiprone. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Deferiprone sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (2)

Certificates of Suitability on the EDQM register for Deferiprone, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
AARTI PHARMALABS LIMITED Mulund (W), MumbaiIN
CEP 2024-124 - Rev 01
Deferiprone
Aug 2026—
KATWIJK CHEMIE BV Katwijk ZHNL
R0-CEP 2020-354 - Rev 00
Deferiprone
Apr 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Deferiprone are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Deferiprone). The latest listed patent expires 25 Oct 2038. The latest listed exclusivity runs to 30 Apr 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Deferiprone is an oral iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia. It forms a stable complex with trivalent iron (Fe3+) and is then eliminated from the body, reducing iron levels and preventing organ damage.

Chemical identity

IUPAC name
3-hydroxy-1,2-dimethylpyridin-4-one
Canonical SMILES
CC1=C(C(=O)C=CN1C)O
InChIKey
TZXKOCQBRNJULO-UHFFFAOYSA-N
Synonyms
Ferriprox API, apo-066, apo-66, cp-20, cp20, deferipron, dn-180-01-af, dn-18001af, l-1, l1, nsc-758880, pl-1

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Iron Chelator
Mechanism of action
Iron Chelating Activity

Therapeutic areas

HematologyGenetic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Deferiprone?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Deferiprone: AARTI PHARMALABS LIMITED (India), Apotex Inc. (Canada), Emcure Pharmaceuticals Limited (India), INDUSTRIALE CHIMICA SRL (Italy), MACSEN DRUGS (India), Taro Pharmaceutical Industries Ltd. (Israel) and KATWIJK CHEMIE BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Deferiprone Drug Master Files are active?

AARTI PHARMALABS LIMITED (DMF 39766), Apotex Inc. (DMF 10867), Emcure Pharmaceuticals Limited (DMF 21640), INDUSTRIALE CHIMICA SRL (DMF 41916), MACSEN DRUGS (DMF 44919) and Taro Pharmaceutical Industries Ltd. (DMF 28983). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Deferiprone records mean?

1 organisation has only inactive Type II DMFs for Deferiprone. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Deferiprone have a European Certificate of Suitability?

Yes. 2 organisations hold a valid CEP for Deferiprone on the EDQM register, including AARTI PHARMALABS LIMITED Mulund (W), Mumbai (IN) and KATWIJK CHEMIE BV Katwijk ZH (NL). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Deferiprone?

Yes. The latest patent listed for an approved US product containing Deferiprone expires 25 Oct 2038, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Deferiprone supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Deferiprone?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.